Back to search

Article

Vasoactive Intestinal Peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis.

2025-05-16

Abstract excerpt

<title>Abstract</title> <p> Current therapies for osteoarthritis (OA) focus on symptom management, rather than halting disease progression. Vasoactive intestinal peptide (VIP) has shown promising effects in musculoskeletal diseases, preserving joint integrity and modulating inflammation. This study investigates the potential of VIP to promote chondrogenic differentiation of human bone marrow mesenchymal stem cel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ceab36a8-c95e-5c76-b485-69c0679eab46
DOI
10.21203/rs.3.rs-6529495/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Vasoactive Intestinal Peptide advances chondrogenesis and modulates pathogenic mediators in human osteoarthritis.DOI 10.21203/rs.3.rs-6529495/v1
Select a neighboring publication to make it the new centre.